Table 3 Characteristics of included control studies
Year/author | Study design | Number of patients/hips (follow-up) | Average age (years) | Gender (M/F) | Initial AVN class (hips) | AVN etiology (patients/hips) | Follow-up time (years) /rate | Validity of the studies | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
TIG | Other | TIG | Other | TIG | Other | TIG | Other | TIG | Other | TIG | Other | |||
2016/Zhao/Chinaa [21] | RCT | 23/23 | 25/25 | 30 ± 7 | 33 ± 8 | 14/9 | 15/10 | ARCO: IIA (4)/IIB (5)/IIC (4)/IIIA (4)/IIIB (4)/IIIC (2) | ARCO: IIA (5)/IIB (5)/IIC (3) IIIA (5)/IIIB (4)/IIIC (3) | Steroid (7 patients)/alcohol (7)/others (9) | Steroid (9 patients)/alcohol (5)/others (11) | 1/100% | 1/100% | Additional file 1: Appendix 2 |
2006/Yen/Chinab [22] | Case-control | 33/39 | 22/22 | 40 (26–63) | 38 (28–52) | 30/3 | 20/2 | Steinberg: II (11)/III (12)/IV (16) | Steinberg: II (4)/III (11)/IV (7) | Steroid (1 patient)/alcohol (15)/idiopathic (17) | Steroid (1 patient)/alcohol (12)/idiopathic (9) | > 4/NA | > 3/NA | Additional file 1: Appendix 2 |
2003/Hasegawa/Japan+c [23] | Case-control | 26/31 | 63/77 | 37.9 (25–53) | 39 (19–64) | 23/3 | 44/19 | Ficat and Arlet: II (28)/III (3) JIC classification: IB (1)/IC (25)/II (4)/III (1) | Ficat and Arlet: II (34)/III (43) JIC classification: IB (3)/IC (62)/II (12) | Steroid (8 hips)/alcohol (16)/idiopathic (7) | Steroid (46 hips)/alcohol (24)/idiopathic (7) | 13 (10–15)/3.84% | 7 (5–11)/3.07% | Additional file 1: Appendix 2 |